Related references
Note: Only part of the references are listed.In-parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance
Francesco Porpiglia et al.
BJU INTERNATIONAL (2016)
PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance
Francesco Cantiello et al.
WORLD JOURNAL OF UROLOGY (2016)
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment
Scott A. Tomlins et al.
EUROPEAN UROLOGY (2016)
Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score
Leander Van Neste et al.
EUROPEAN UROLOGY (2016)
A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy
James McKiernan et al.
JAMA ONCOLOGY (2016)
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer
Claire L. Tonry et al.
DIAGNOSTICS (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer
Gisele H. J. M. Leyten et al.
CLINICAL CANCER RESEARCH (2015)
A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer
Dipen J. Parekh et al.
EUROPEAN UROLOGY (2015)
Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer
Tobias Nordstrom et al.
EUROPEAN UROLOGY (2015)
Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study
Nicola Fossati et al.
EUROPEAN UROLOGY (2015)
The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation
Amanda Nicholson et al.
HEALTH TECHNOLOGY ASSESSMENT (2015)
A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result
M. J. Donovan et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2015)
Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy
Francesco Cantiello et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2015)
Accuracy of the Prostate Health Index Versus the Urinary Prostate Cancer Antigen 3 Score to Predict Overall and Significant Prostate Cancer at Initial Biopsy
Thomas Seisen et al.
PROSTATE (2015)
Fluctuation in prostate cancer gene 3 (PCA3) score in men undergoing first or repeat prostate biopsies
Stefano De Luca et al.
BJU INTERNATIONAL (2014)
Prospective Multicentre Evaluation of PCA3 and TMPRSS2-ERG Gene Fusions as Diagnostic and Prognostic Urinary Biomarkers for Prostate Cancer
Gisele H. J. M. Leyten et al.
EUROPEAN UROLOGY (2014)
Novel Tools to Improve Patient Selection and Monitoring on Active Surveillance for Low-risk Prostate Cancer: A Systematic Review
Roderick C. N. van den Bergh et al.
EUROPEAN UROLOGY (2014)
Comparative Evaluation of Urinary PCA3 and TMPRSS2: ERG Scores and Serum PHI in Predicting Prostate Cancer Aggressiveness
Lucile Tallon et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
The Roles of Multiparametric Magnetic Resonance Imaging, PCA3 and Prostate Health Index-Which is the Best Predictor of Prostate Cancer after a Negative Biopsy?
Francesco Porpiglia et al.
JOURNAL OF UROLOGY (2014)
The Prostate Health Index: a new test for the detection of prostate cancer
Stacy Loeb et al.
THERAPEUTIC ADVANCES IN UROLOGY (2014)
Urinary biomarkers for prostate cancer: a review
Daphne Hessels et al.
ASIAN JOURNAL OF ANDROLOGY (2013)
Comparative Assessment of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG Gene Fusion with the Serum [-2]Proprostate-Specific Antigen-Based Prostate Health Index for Detection of Prostate Cancer
Carsten Stephan et al.
CLINICAL CHEMISTRY (2013)
Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study
Meelan Bul et al.
EUROPEAN UROLOGY (2013)
Head-to-Head Comparison of Prostate Health Index and Urinary PCA3 for Predicting Cancer at Initial or Repeat Biopsy
Vincenzo Scattoni et al.
JOURNAL OF UROLOGY (2013)
Toward the Detection of Prostate Cancer in Urine: A Critical Analysis
Matthew Truong et al.
JOURNAL OF UROLOGY (2013)
Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2-10 ng/ml
Matteo Ferro et al.
PLOS ONE (2013)
Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer
Jean-Nicolas Cornu et al.
PROSTATE (2013)
Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy
Sisto Perdona et al.
PROSTATE (2013)
Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer
Simpa S. Salami et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2013)
Recurrent Gene Fusions in Prostate Cancer: Their Clinical Implications and Uses
Daphne Hessels et al.
CURRENT UROLOGY REPORTS (2013)
The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis
Andreas Pettersson et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2012)
Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers
Matteo Ferro et al.
CLINICA CHIMICA ACTA (2012)
Molecular Diagnosis of Prostate Cancer: PCA3 and TMPRSS2:ERG Gene Fusion
Maciej Salagierski et al.
JOURNAL OF UROLOGY (2012)
Prostate-Specific Antigen (PSA) Isoform p2PSA Significantly Improves the Prediction of Prostate Cancer at Initial Extended Prostate Biopsies in Patients with Total PSA Between 2.0 and 10 ng/ml: Results of a Prospective Study in a Clinical Setting
Giorgio Guazzoni et al.
EUROPEAN UROLOGY (2011)
A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range
William J. Catalona et al.
JOURNAL OF UROLOGY (2011)
False-negative Prostate Needle Biopsies: Frequency, Histopathologic Features, and Follow-up
Tineke Wolters et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?
Guillaume Ploussard et al.
BJU INTERNATIONAL (2010)
A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [-2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness
Lori J. Sokoll et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2010)
Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: An Independent Replication
Andrew Vickers et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis
Kari Rostad et al.
APMIS (2009)
Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer
J. Nilsson et al.
BRITISH JOURNAL OF CANCER (2009)
Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context
Gerrit Draisma et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Screening and Prostate-Cancer Mortality in a Randomized European Study
Fritz H. Schroeder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden
Andrew J. Vickers et al.
BMC MEDICINE (2008)
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers
Ashish B. Rajput et al.
JOURNAL OF CLINICAL PATHOLOGY (2007)
Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer
Daphne Hessels et al.
CLINICAL CANCER RESEARCH (2007)
TMPRSS2-ERG fusion prostate cancer:: An early molecular event associated with invasion
Sven Perner et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2007)
PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy
Leonard S. Marks et al.
UROLOGY (2007)
APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer
Jack Groskopf et al.
CLINICAL CHEMISTRY (2006)
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
SA Tomlins et al.
SCIENCE (2005)
Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer
SD Mikolajczyk et al.
CLINICAL CHEMISTRY (2004)
Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter
IM Thompson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer
D Hessels et al.
EUROPEAN UROLOGY (2003)
New targets for therapy in prostate cancer: Differential display code 3 (DD3(PCA3)) a highly prostate cancer-specific gene
JA Schalken et al.
UROLOGY (2003)